Drugs / RBT-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04072432 | Oct 2018 → Mar 2019 | chronic kidney disease | Renibus Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RBT-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04072432 ↗ |
| Route | Intravenous | “intravenous administration” NCT04072432 ↗ |